Jardiance empagliflozin regulatory update

EMA's CHMP backed approval of Jardiance empagliflozin from Boehringer Ingelheim and partner Eli Lilly as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes. CHMP backed approval of empagliflozin as monotherapy when diet and exercise alone do not provide adequate glycemic control in patients for whom metformin is considered inappropriate; and as add-on therapy with other glucose-lowering products, including insulin, when these products together with diet and exercise do not provide adequate glycemic control. ...